NASDAQ:DRIO DarioHealth (DRIO) Stock Forecast, Price & News $3.90 +0.06 (+1.56%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$3.81▼$4.0050-Day Range$3.20▼$4.1252-Week Range$3.13▼$7.69Volume86,054 shsAverage Volume151,479 shsMarket Capitalization$102.80 millionP/E RatioN/ADividend YieldN/APrice Target$11.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media DarioHealth MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside192.3% Upside$11.40 Price TargetShort InterestBearish7.74% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($1.70) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.46 out of 5 starsMedical Sector940th out of 1,006 stocksSurgical & Medical Instruments Industry95th out of 104 stocks 3.5 Analyst's Opinion Consensus RatingDarioHealth has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.40, DarioHealth has a forecasted upside of 192.3% from its current price of $3.90.Amount of Analyst CoverageDarioHealth has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted7.74% of the outstanding shares of DarioHealth have been sold short.Short Interest Ratio / Days to CoverDarioHealth has a short interest ratio ("days to cover") of 12.7, which indicates bearish sentiment.Change versus previous monthShort interest in DarioHealth has recently increased by 9.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDarioHealth does not currently pay a dividend.Dividend GrowthDarioHealth does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DRIO. Previous Next 1.4 News and Social Media Coverage News SentimentDarioHealth has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for DarioHealth this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for DRIO on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DarioHealth insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.40% of the stock of DarioHealth is held by insiders.Percentage Held by InstitutionsOnly 35.78% of the stock of DarioHealth is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DarioHealth are expected to grow in the coming year, from ($1.87) to ($1.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DarioHealth is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DarioHealth is -2.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDarioHealth has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DarioHealth (NASDAQ:DRIO) StockDarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. Its solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.Read More Receive DRIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address DRIO Stock News HeadlinesMay 18, 2023 | finance.yahoo.comMedOne Launches Dario's Digital Health Solution to Help Members Improve Health with a Personalized SupportMay 16, 2023 | finance.yahoo.comDarioHealth Corp. (NASDAQ:DRIO) Q1 2023 Earnings Call TranscriptMay 31, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 13, 2023 | americanbankingnews.comDarioHealth (NASDAQ:DRIO) Given New $6.00 Price Target at Alliance Global PartnersMay 13, 2023 | americanbankingnews.comDarioHealth (NASDAQ:DRIO) PT Lowered to $8.00 at Craig HallumMay 12, 2023 | msn.comCraig-Hallum Maintains DarioHealth (DRIO) Buy RecommendationMay 12, 2023 | marketwatch.comInvestorNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Announces Q1 Financial and Operating ResultsMay 11, 2023 | finanznachrichten.deDarioHealth Corp.: DarioHealth Reports First Quarter Financial and Operating ResultsMay 31, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 11, 2023 | finance.yahoo.comDarioHealth Reports First Quarter Financial and Operating ResultsMay 10, 2023 | msn.comDarioHealth Q1 2023 Earnings PreviewMay 10, 2023 | marketwatch.comInvestorNewsBreaks - DarioHealth Corp. (NASDAQ: DRIO) Reports on Research Presented at Leading Global Conference for Health EconomicsMay 9, 2023 | finance.yahoo.comSanofi research demonstrates 9.3% reduction in all-cause healthcare resource utilization rates, including 23.5% decrease in hospitalization for Dario usersMay 5, 2023 | finance.yahoo.comDarioHealth Corp. (NASDAQ:DRIO) Might Not Be As Mispriced As It LooksMay 4, 2023 | finance.yahoo.comDarioHealth to Report First Quarter 2023 Results on Thursday, May 11thMay 2, 2023 | finance.yahoo.comDarioHealth Announces $14.3 Million Private PlacementApril 30, 2023 | americanbankingnews.comDarioHealth (NASDAQ:DRIO) and Invo Bioscience (OTCMKTS:IVOB) Critical AnalysisApril 16, 2023 | uk.finance.yahoo.comDarioHealth Corp. (DRIO) stock historical prices & data – Yahoo FinanceApril 4, 2023 | finance.yahoo.comDigital Health Product Leader, Eitan Shay, Joins Dario as Chief Product OfficerMarch 31, 2023 | americanbankingnews.comBrokers Offer Predictions for DarioHealth Corp.'s Q1 2023 Earnings (NASDAQ:DRIO)March 30, 2023 | markets.businessinsider.comLifeSci Capital Sticks to Their Buy Rating for DarioHealth (DRIO)March 27, 2023 | finance.yahoo.comDario Selected as Digital Therapeutics Partner by a Top-Ten Digitally Enabled Pharmacy Benefits ManagerMarch 26, 2023 | americanbankingnews.comAnalyzing Nemaura Medical (NASDAQ:NMRD) and DarioHealth (NASDAQ:DRIO)March 14, 2023 | finance.yahoo.comDario Publishes New Research Demonstrating Digital Personalization of Pain Management with Adapted Machine LearningMarch 12, 2023 | finance.yahoo.comThe DarioHealth Corp. (NASDAQ:DRIO) Annual Results Are Out And Analysts Have Published New ForecastsMarch 9, 2023 | finance.yahoo.comDarioHealth Reports Fourth Quarter and Record Revenue in Full-Year 2022 Financial and Operating ResultsMarch 2, 2023 | finance.yahoo.comDarioHealth to Report Fourth Quarter 2022 Results on Thursday, March 9thSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DRIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter. Email Address DRIO Company Calendar Last Earnings3/09/2023Today5/31/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRIO CUSIPN/A CIK1533998 Webwww.mydario.com Phone(833) 914-3796Fax972-4770-4059Employees200Year Founded2011Price Target and Rating Average Stock Price Forecast$11.40 High Stock Price Forecast$15.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+196.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,190,000.00 Net Margins-125.46% Pretax Margin-221.65% Return on Equity-39.28% Return on Assets-27.26% Debt Debt-to-Equity Ratio0.23 Current Ratio3.15 Quick Ratio2.76 Sales & Book Value Annual Sales$27.66 million Price / Sales3.66 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book1.41Miscellaneous Outstanding Shares26,360,000Free Float23,883,000Market Cap$101.22 million OptionableNot Optionable Beta1.35 Social Links Key ExecutivesErez RaphaelChief Executive Officer & DirectorRichard Allen AndersonPresident & General Manager-North America RegionJoshua FischerSVP-Operations & ComplianceZvi Ben-DavidChief Financial Officer, Secretary & TreasurerMichal HershkovitzVice President-Clinical, Regulatory Affairs & QAKey CompetitorsNeuroPaceNASDAQ:NPCEAkiliNASDAQ:AKLIDelcath SystemsNASDAQ:DCTHLyra TherapeuticsNASDAQ:LYRACytosorbentsNASDAQ:CTSOView All CompetitorsInsiders & InstitutionsAppian Way Asset Management LPSold 121,196 shares on 5/16/2023Ownership: 3.880%Perceptive Advisors LLCSold 14,000 shares on 5/16/2023Ownership: 1.191%Susquehanna International Group LLPSold 7,132 shares on 5/16/2023Ownership: 0.229%BlackRock Inc.Bought 3,644 shares on 5/12/2023Ownership: 0.569%Group One Trading L.P.Bought 300 shares on 5/12/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions DRIO Stock - Frequently Asked Questions Should I buy or sell DarioHealth stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRIO shares. View DRIO analyst ratings or view top-rated stocks. What is DarioHealth's stock price forecast for 2023? 4 equities research analysts have issued 1-year price targets for DarioHealth's shares. Their DRIO share price forecasts range from $6.00 to $15.00. On average, they expect the company's stock price to reach $11.40 in the next year. This suggests a possible upside of 196.9% from the stock's current price. View analysts price targets for DRIO or view top-rated stocks among Wall Street analysts. How have DRIO shares performed in 2023? DarioHealth's stock was trading at $4.28 at the beginning of 2023. Since then, DRIO stock has decreased by 10.3% and is now trading at $3.84. View the best growth stocks for 2023 here. Are investors shorting DarioHealth? DarioHealth saw a increase in short interest in May. As of May 15th, there was short interest totaling 2,040,000 shares, an increase of 9.7% from the April 30th total of 1,860,000 shares. Based on an average trading volume of 161,100 shares, the short-interest ratio is presently 12.7 days. View DarioHealth's Short Interest. When is DarioHealth's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our DRIO earnings forecast. How were DarioHealth's earnings last quarter? DarioHealth Corp. (NASDAQ:DRIO) announced its earnings results on Thursday, March, 9th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.09. The firm earned $6.81 million during the quarter, compared to the consensus estimate of $6.65 million. DarioHealth had a negative trailing twelve-month return on equity of 39.28% and a negative net margin of 125.46%. During the same quarter in the previous year, the business earned ($1.09) earnings per share. What other stocks do shareholders of DarioHealth own? Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL). What is DarioHealth's stock symbol? DarioHealth trades on the NASDAQ under the ticker symbol "DRIO." Who are DarioHealth's major shareholders? DarioHealth's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Appian Way Asset Management LP (3.88%), Perceptive Advisors LLC (1.19%), BlackRock Inc. (0.57%), MAI Capital Management (0.56%), Susquehanna International Group LLP (0.23%) and Renaissance Technologies LLC (0.22%). Insiders that own company stock include Dennis M Mcgrath, Dror Bacher, Erez Raphael and Oded Cohen. View institutional ownership trends. How do I buy shares of DarioHealth? Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DarioHealth's stock price today? One share of DRIO stock can currently be purchased for approximately $3.84. How much money does DarioHealth make? DarioHealth (NASDAQ:DRIO) has a market capitalization of $101.22 million and generates $27.66 million in revenue each year. The company earns $-62,190,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. How many employees does DarioHealth have? The company employs 200 workers across the globe. Does DarioHealth have any subsidiaries? The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..Read More How can I contact DarioHealth? DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059. This page (NASDAQ:DRIO) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DarioHealth Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.